Cannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suiteA systematic review of the antipsychotic properties of cannabidiol in humans T.A. Iseger, M.G. Bossong Schizophrenia Research, 2015, 162, (1-3), 153-161 doi: 10.1016/j.schres.2015.01.033 Abstract Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces acute psychotic effects and cognitive impairment. However, the non-psychotropic, plant-derived cannabinoid agent cannabidiol (CBD) [...]
Lire la suiteA Systematic Review on the Pharmacokinetics of Cannabidiol in Humans Sophie A. Millar, Nicole L. Stone, Andrew S. Yates and Saoirse E. O’Sullivan Frontiers in Pharmacology, 26 November 2018 https://doi.org/10.3389/fphar.2018.01365 Background : Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods : A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results : Of 792 articles retireved, 24 included [...]
Lire la suiteThe Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis Britta Hahn Schizophrenia Bulletin, 2018, vol. 44, no. 1, 46–53 doi:10.1093/schbul/sbx105 A major factor associated with poor prognostic outcome after a first psychotic break is cannabis misuse, which is prevalent in schizophrenia and particularly common in individuals with recent-onset psychosis. Behavioral interventions aimed at reducing cannabis use have been unsuccessful in this population. Cannabidiol (CBD) is a phytocannabinoid found in cannabis, although at low concentrations in modern-day strains. CBD has a broad pharmacological profile, but contrary to Δ9-tetrahydrocannabinol (THC), CBD does not activate CB1 or CB2 receptors and has at most subtle subjective [...]
Lire la suiteUS Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013 Deborah S. Hasin, Aaron L. Sarvet, Magdalena Cerda, Katherine M. Keyes, Malka Stohl, Sandro Galea, Melanie M. Wall JAMA Psychiatry, 2017, 74, (6), 579–610. Doi : 10.1001/jamapsychiatry.2017.0724 PMCID: PMC5539836 PMID: 28445557 Key Points Question Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s? Findings In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118 497 participants, the risk for cannabis use and cannabis use disorders increased at a significantly [...]
Lire la suiteCannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort Gabrielle Campbell, Wayne D. Hall, Amy Peacock, Nicholas Lintzeris, Raimondo Bruno, Briony Larance, Suzanne Nielsen, Milton Cohen, Gary Chan, Richard P. Mattick, Fiona Blyth, Marian Shanahan, Timothy Dobbins, Michael Farrell, Louisa Degenhardt Lancet Public Health, 2018, 3, (7): e341–e350. doi:10.1016/S2468-2667(18)30110-5. Abstract Background : There has been growing interest in the use of cannabis and cannabinoids to treat chronic non-cancer pain (CNCP). Cannabis and cannabinoids have attracted attention because of their greater safety compared with opioids, and the possibility that their use can reduce opioid [...]
Lire la suiteThe effect of cannabis laws on opioid use. J.L. Flexon, L. Stolzenberg, S.J. d'Alessio International Journal of Drug Policy, 2019, 74, 152-159. doi : 10.1016/j.drugpo.2019.09.013. Abstract BACKGROUND : Many Americans rely on opioids at varying dosages to help ameliorate their suffering. However, empirical evidence is mounting that opioids are ineffective at controlling non-cancer related chronic pain, and many argue the strategies meant to relieve patient suffering are contributing to the growing opioid epidemic. Concurrently, several states now allow the use of medical cannabis to treat a variety of medical conditions, including chronic pain. Needing more exploration is the impact of cannabis laws on general opioid reliance [...]
Lire la suiteHippocampal Neurotoxicity of D9-Tetrahydrocannabinol Guy Chiu-Kai Chan, Thomas R. Hinds, Soren Impey, and Daniel R. Storm The Journal of Neuroscience, 1998, 18, (14), 5322–5332 Marijuana consumption elicits diverse physiological and psychological effects in humans, including memory loss. Here we report that D9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is toxic for hippocampal neurons. Treatment of cultured neurons or hippocampal slices with THC caused shrinkage of neuronal cell bodies and nuclei as well as genomic DNA strand breaks, hallmarks of neuronal apoptosis. Neuron death induced by THC was inhibited by nonsteroidal anti-inflammatory drugs, including indomethacin and aspirin, as well as vitamin E and [...]
Lire la suiteThe Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study Gil Bar-Sela, Daniela Zalman, Valerya Semenysty and Eyal Ballan Integrative Cancer Therapies, 2019, Volume 18, 1–8 DOI: 10.1177/1534735419881498 Abstract Background : Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients. Methods : The cannabis capsules used in this study contained two fractions of oil-based compounds. The planned treatment was [...]
Lire la suiteCannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette Journal of Neuroscience, 2019, 39, (44), 8762-8777 Doi : https://doi.org/10.1523/JNEUROSCI.0708-19.2019 Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency [...]
Lire la suite